Price (delayed)
$1.57
Market cap
$25.23M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.7
Enterprise value
$22.69M
NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped
There are no recent dividends present for NNVC.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.